PhRMA Must Restart Suit Over 340B Orphan Drug Rule
A Washington, D.C., federal judge on Wednesday rejected requests from Pharmaceutical Research and Manufacturers of America to invalidate a new interpretive rule involving so-called orphan drugs in the 340B drug discount...To view the full article, register now.
Already a subscriber? Click here to view full article